Patents by Inventor Millard Hurst Lambert

Millard Hurst Lambert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11976057
    Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: May 7, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Edward Brnardic, Michael Bury, Rodolfo Cadilla, Jon Collins, Yu Guo, Anthony Handlon, Huijie Li, Yue Li, Daniel Paone, Christie Schulte, Barry Shearer, Maben Ying, Guosen Ye, Huichang Zhang, Millard Hurst Lambert, III
  • Publication number: 20100240642
    Abstract: The present invention relates to certain indole derivatives that are modulators of PPAR?, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.
    Type: Application
    Filed: August 31, 2007
    Publication date: September 23, 2010
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Jeffrey Alan Oplinger, Paul Kenneth Spearing, Millard Hurst Lambert, John A. Ray, Christopher P. Laudeman, Jerzy R. Szewczyk, Pierette Banker
  • Publication number: 20100105749
    Abstract: The present invention provides compounds of the formulae (I) and (II), and derivatives thereof, for the treatment of cardiovascular conditions
    Type: Application
    Filed: January 30, 2008
    Publication date: April 29, 2010
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Jon Loren Collins, Jodi Maglich Goodwin, Millard Hurst Lambert, III
  • Patent number: 7449468
    Abstract: The present invention provides a compound of formula (I): wherein R1-R5, R25, R26, Y, y, and X2are as defined herein. The compounds activate human peroxisome proliferater activated receptors (hPPARs) and are useful for the treatment of associated disorders such as dyslipidemia, syndrome X, hypercholesteremia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, and obesity.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: November 11, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Pierette Banker, Rodolfo Cadilla, Millard Hurst Lambert, III, Stephen William Rafferty, Daniel David Sternbach, Marcos Luis Sznaidman
  • Patent number: 7439259
    Abstract: The present invention provides combinations of compounds of formula (I) and other therapeutic agents for the treatment of PPAR related diseases.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: October 21, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Rodolfo Cadilla, Romain Luc Marie Gosmini, Millard Hurst Lambert, III, Michael Lawrence Sierra
  • Patent number: 7229998
    Abstract: The present invention provides a compound of formula (I): wherein R1–R5, R25, R26, Y and X2 are as defined herein. The compounds activate human peroxisome proliferator activated receptors (hPPARs) and are useful for the treatment of associated disorders such as cardiovascular disease and hypercholesteremia.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: June 12, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Rodolfo Cadilla, Millard Hurst Lambert, III, Stephen William Rafferty, Daniel David Sternbach
  • Patent number: 7199239
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, Wherein: R1 and R2 are independently hydrogen or C1-3 alkyl; X represents a bond, CH2 or O; R3 and R4 are independently hydrogen, C1-6 alkyl, OCH3, CF3, allyl or halogen; X1 is CH2, SO2, or CO; R5 is —C1-6 alkyl (optionally substituted by C1-6alkoxy or C1-6alkylthio), —C2-6 alkenyl, —C0-6 alkyl phenyl (wherein the phenyl is optionally substituted by one or more CF3, halogen, C1-3 alkyl, C1-3 alkoxy), —COC1-6 alkyl, SO2C1-6 alkyl; R6 is phenyl or a 6 membered heteroaryl group containing 1, 2 or 3 N atoms wherein the phenyl or heteroaryl group is optionally substituted with 1, 2 or 3 moieties selected from the group consisting of C1-6 alkyl, halogen, —OC1-6 alkyl, —SO2C1-3 alkyl, phenyl (optionally substituted by one or more groups selected from halogen, CF3, C1-3 alkyl, OC1-3 alkyl, acetyl, CN).
    Type: Grant
    Filed: June 18, 2003
    Date of Patent: April 3, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Paul John Beswick, John David Harling, Savvas Kleanthous, Millard Hurst Lambert, III, Vipulkumar Kantibhai Patel, Juliet Simpson
  • Patent number: 7105551
    Abstract: The present invention provides compounds of formula (I).
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: September 12, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Rodolfo Cadilla, Romain Luc Marie Gosmini, Millard Hurst Lambert, III, Michael Lawrence Sierra
  • Patent number: 6943162
    Abstract: Triazine derivatives of formula (I), which exhibit pharmacological activity at estrogen receptors alpha (ER alpha) and beta (ER beta) are described herein. The described invention also includes compositions and medicaments containing the triazine derivatives as well as processes for the preparation and use of such compounds, compositions and medicaments.
    Type: Grant
    Filed: January 23, 2002
    Date of Patent: September 13, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: Ronnie Lee Hale, Brad Richard Henke, Millard Hurst Lambert, III, Amy Tsai Lu, Paul Kenneth Spearing, Philip Stewart Turnbull
  • Publication number: 20040137518
    Abstract: A solved three-dimensional crystal structure of a PPAR&agr; ligand binding domain polypeptide is disclosed, along with a crystal form of the PPAR&agr; ligand binding domain polypeptide. Methods of designing modulators of the biological activity of PPAR&agr; and other PPAR ligand binding domain polypeptides are also disclosed.
    Type: Application
    Filed: August 1, 2003
    Publication date: July 15, 2004
    Inventors: Millard Hurst Lambert, Valerie Gail Montana, Huaqiang Eric Xu
  • Patent number: 6723740
    Abstract: Compounds of Formula (I) are disclosed. These compounds selected activators of human PPAR delta.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: April 20, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Esther Yu-Hsuan Chao, Curt Dale Haffner, Millard Hurst Lambert, III, Patrick Reed Maloney, Michael Lawrence Sierra, Daniel David Sternbach, Marcos Luis Sznaidman, Timothy Mark Willson, Huaqiang Eric Xu
  • Publication number: 20040072829
    Abstract: Triazine derivatives of formula (I), which exhibit pharmacological activity at estrogen receptors alpha (ER alpha) and beta (ER beta) are described herein. The described invention also includes compositions and medicaments containing the triazine derivatives as well as processes for the preparation and use of such compounds, compositions and medicaments.
    Type: Application
    Filed: July 21, 2003
    Publication date: April 15, 2004
    Inventors: Ronnie Lee Hale, Brad Richard Henke, Millard Hurst Lambert III, Amy Tsai Lu, Paul Kenneth Spearing, Philip Stewart Turnball
  • Publication number: 20040072838
    Abstract: The present invention provides a compound of formula (1) wherein R1-R5, R25, R26, Y and X2 are defined as in claim 1. The compounds activate human peroxisome proliferator activated receptors (hPPARs) and arc useful for the treatment of associated disorders such as cardiovascular disease and hypercholesteremia.
    Type: Application
    Filed: October 31, 2003
    Publication date: April 15, 2004
    Inventors: Pierette Banker, Rodolfo Cadilla, Millard Hurst Lambert lll, Stephen William Rafferty, Daniel David Sternbach, Marcos Luis Sznaidman
  • Patent number: 6710063
    Abstract: Compounds of Formula (1) are disclosed. These compounds include selective activators of human PPAR delta.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: March 23, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Esther Yu-Hsuan Chao, Curt Dale Haffner, Millard Hurst Lambert, III, Patrick Reed Maloney, Michael Lawrence Sierra, Daniel David Sternbach, Marcos Luis Sznaidman, Timothy Mark Willson, Huaqiang Eric Xu
  • Publication number: 20030203947
    Abstract: Compounds of Formula (I) are disclosed. These compounds include selective activators of human PPAR delta.
    Type: Application
    Filed: March 6, 2003
    Publication date: October 30, 2003
    Inventors: Esther Yu-Hsuan Chao, Curt Dale Haffner, Millard Hurst Lambert, Patrick Reed Maloney, Michael Lawrence Sierra, Daniel David Sternbach, Marcos Luis Sznaidman, Timothy Mark Willson, Huaqiang Eric Xu
  • Patent number: 6506781
    Abstract: A method is disclosed for rational design of a PPAR, FXR, LXR-alpha, or LXR-beta antagonist comprising chemical modification of a PPAR, FXR, LXR-alpha, or LXR-beta agonist to: a) prevent formation of a hydrogen bond between the agonist and tyrosine or histidine, or tryptophan involved in receptor activation; and/or b) displace the tyrosine or histidine, or tryptophan involved in receptor activation from its agonist bound position. Preferably, little or no additional changes are made in the structure of the agonist so that the resulting antagonist is a close structural analogue of the agonist.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: January 14, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Jeffrey Edmond Cobb, Millard Hurst Lambert, III, Michael Vance Milburn, Barry George Shearer